{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:40:33Z","timestamp":1787164833636,"version":"build-2736575974"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11302-025-10114-6","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:24:23Z","timestamp":1773026663000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The potential role of adenosinergic pathway and methylxanthines in Parkinson\u2019s disease: Blowing in the wind or not"],"prefix":"10.1007","volume":"22","author":[{"given":"Alaa","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luay M.","family":"Alkazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Faisal","family":"Albukhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa M.","family":"Shokr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"10114_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102075","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK (2023) The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2023.102075","journal-title":"Ageing Res Rev"},{"key":"10114_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12035-023-03561-y","volume":"61","author":"SA Alnaaim","year":"2024","unstructured":"Alnaaim SA, Al-Kuraishy HM, Alexiou A, Papadakis M, Saad HM, Batiha GES (2024) Role of brain liver X receptor in Parkinson\u2019s disease: hidden treasure and emerging opportunities. Mol Neurobiol 61:341\u2013357. https:\/\/doi.org\/10.1007\/s12035-023-03561-y","journal-title":"Mol Neurobiol"},{"key":"10114_CR3","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1007\/s10571-023-01350-8","volume":"43","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Elewa YHA, Zahran MH, Alexiou A, Papadakis M, Batiha GES (2023) Parkinson\u2019s disease risk and hyperhomocysteinemia: the possible link. Cell Mol Neurobiol 43:2743\u20132759. https:\/\/doi.org\/10.1007\/s10571-023-01350-8","journal-title":"Cell Mol Neurobiol"},{"key":"10114_CR4","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/jnr.25171","volume":"101","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Kaushik A, Kujawska M, Ahmed EA, Batiha GES (2023) SARS-COV-2 infection and Parkinson\u2019s disease: possible links and perspectives. J Neurosci Res 101:952\u2013975. https:\/\/doi.org\/10.1002\/jnr.25171","journal-title":"J Neurosci Res"},{"key":"10114_CR5","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s12035-023-03727-8","volume":"61","author":"NH Ali","year":"2024","unstructured":"Ali NH, Al-kuraishy HM, Al-Gareeb AI, Alnaaim SA, Saad HM, Batiha GES (2024) The molecular pathway of p75 neurotrophin receptor (p75NTR) in Parkinson\u2019s disease: the way of new inroads. Mol Neurobiol 61:2469\u20132480. https:\/\/doi.org\/10.1007\/s12035-023-03727-8","journal-title":"Mol Neurobiol"},{"key":"10114_CR6","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1007\/s10072-023-06926-2","volume":"44","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Al-Kuraishy HM, Al-Mahammadawy AK, Al-Gareeb AI, Saad HM, Batiha GE (2023) The potential role of cholesterol in Parkinson\u2019s disease neuropathology: perpetrator or victim. Neurol Sci 44:3781\u20133794. https:\/\/doi.org\/10.1007\/s10072-023-06926-2","journal-title":"Neurol Sci"},{"key":"10114_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00210-023-02656-6","volume":"397","author":"HM Al-kuraishy","year":"2024","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Selim HM, Alexiou A, Papadakis M, Negm WA, Batiha GES (2024) Does vitamin D protect or treat Parkinson\u2019s disease? A narrative review. Naunyn Schmiedebergs Arch Pharmacol 397:33\u201340. https:\/\/doi.org\/10.1007\/s00210-023-02656-6","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10114_CR8","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.1007\/s11033-023-08459-5","volume":"50","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Zaafar D, Batiha GES (2023) Orexin pathway in Parkinson\u2019s disease: a review. Mol Biol Rep 50:6107\u20136120. https:\/\/doi.org\/10.1007\/s11033-023-08459-5","journal-title":"Mol Biol Rep"},{"key":"10114_CR9","doi-asserted-by":"publisher","first-page":"0","DOI":"10.1002\/iid3.1100","volume":"11","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Al-Maiahy TJ, Al-Gareeb AI, Alexiou A, Papadakis M, Elhussieny O, Saad HM, Batiha GES (2023) New insights on the potential effect of progesterone in COVID-19: anti-inflammatory and immunosuppressive effects. Immun Inflamm Dis 11:0\u20131. https:\/\/doi.org\/10.1002\/iid3.1100","journal-title":"Immun Inflamm Dis"},{"key":"10114_CR10","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1111\/jcmm.17784","volume":"27","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Al-kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Jabir MS, Saad HM, Batiha GES (2023) NF-\u03baB\/NLRP3 inflammasome axis and risk of Parkinson\u2019s disease in type 2 diabetes mellitus: a narrative review and new perspective. J Cell Mol Med 27:1775\u20131789. https:\/\/doi.org\/10.1111\/jcmm.17784","journal-title":"J Cell Mol Med"},{"key":"10114_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10787-022-01125-5","volume":"31","author":"GES Batiha","year":"2023","unstructured":"Batiha GES, Al-kuraishy HM, Al-Gareeb AI, Elekhnawy E (2023) SIRT1 pathway in Parkinson\u2019s disease: a faraway snapshot but so close. Inflammopharmacology 31:37\u201356. https:\/\/doi.org\/10.1007\/s10787-022-01125-5","journal-title":"Inflammopharmacology"},{"key":"10114_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102143","author":"HM Al-kuraishy","year":"2024","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Zaidalkiani AT, Alexiou A, Papadakis M, Bahaa MM, AL-Faraga A, Batiha GES (2024) Calprotectin in Parkinsonian disease: anticipation and dedication. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2023.102143","journal-title":"Ageing Res Rev"},{"key":"10114_CR13","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s43440-023-00500-5","volume":"75","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Al-kuraishy HM, Al-buhadily AK, Al-Gareeb AI, Elekhnawy E, Batiha GES (2023) DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson\u2019s disease: a mutual relationship. Pharmacol Rep 75:923\u2013936. https:\/\/doi.org\/10.1007\/s43440-023-00500-5","journal-title":"Pharmacol Rep"},{"key":"10114_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s11010-023-04771-7","volume":"479","author":"M Alrouji","year":"2024","unstructured":"Alrouji M, Al-kuraishy HM, Al-Gareeb AI, Ashour NA, Jabir MS, Negm WA, Batiha GES (2024) Metformin role in Parkinson\u2019s disease: a double-sword effect. Mol Cell Biochem 479:975\u2013991. https:\/\/doi.org\/10.1007\/s11010-023-04771-7","journal-title":"Mol Cell Biochem"},{"key":"10114_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4103\/bc.bc_42_19","volume":"6","author":"H Al-Kuraishy","year":"2020","unstructured":"Al-Kuraishy H, Abdulhadi M, Hussien N, Al-Niemi M, Rasheed H, Al-Gareeb A (2020) Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review. Brain Circ 6:70. https:\/\/doi.org\/10.4103\/bc.bc_42_19","journal-title":"Brain Circ"},{"key":"10114_CR16","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00210-023-02726-9","volume":"397","author":"NH Ali","year":"2024","unstructured":"Ali NH, Alhamdan NA, Al-kuraishy HM, Al-Gareeb AI, Elekhnawy E, Batiha GES (2024) Irisin\/PGC-1\u03b1\/FNDC5 pathway in Parkinson\u2019s disease: truth under the throes. Naunyn-Schmiedebergs Arch Pharmacol 397:1985\u20131995. https:\/\/doi.org\/10.1007\/s00210-023-02726-9","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10114_CR17","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer P, Van Den Berge N (2019) Brain-First versus Gut-First Parkinson\u2019s disease: a hypothesis. J Parkinsons Dis 9:S281\u2013S295. https:\/\/doi.org\/10.3233\/JPD-191721","journal-title":"J Parkinsons Dis"},{"key":"10114_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126517","volume":"22","author":"A Cardinale","year":"2021","unstructured":"Cardinale A, Calabrese V, de Iure A, Picconi B (2021) Alpha-synuclein as a prominent actor in the inflammatory synaptopathy of parkinson\u2019s disease. Int J Mol Sci 22:6517. https:\/\/doi.org\/10.3390\/ijms22126517","journal-title":"Int J Mol Sci"},{"key":"10114_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/bph.15684","volume":"179","author":"ME Haque","year":"2022","unstructured":"Haque ME, Akther M, Azam S, Kim IS, Lin Y, Lee YH, Choi DK (2022) Targeting \u03b1-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson\u2019s disease. Br J Pharmacol 179:23\u201345. https:\/\/doi.org\/10.1111\/bph.15684","journal-title":"Br J Pharmacol"},{"key":"10114_CR20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00702-019-02025-9","volume":"126","author":"P Riederer","year":"2019","unstructured":"Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Kr\u00fcger R, M\u00fcller T, Reichmann H, Rie\u00df O, Storch A, Strobel S, van Eimeren T, V\u00f6lker HU, Winkler J, Winklhofer KF, W\u00fcllner U, Zunke F, Monoranu CM (2019) \u03b1-Synuclein in Parkinson\u2019s disease: causal or bystander? J Neural Transm 126:815\u2013840. https:\/\/doi.org\/10.1007\/s00702-019-02025-9","journal-title":"J Neural Transm"},{"key":"10114_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/mds.28411","volume":"36","author":"EM Kline","year":"2021","unstructured":"Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG (2021) Genetic and environmental factors in Parkinson\u2019s disease converge on immune function and inflammation. Mov Disord 36:25\u201336. https:\/\/doi.org\/10.1002\/mds.28411","journal-title":"Mov Disord"},{"key":"10114_CR22","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1111\/ejn.14699","volume":"53","author":"ST Feng","year":"2021","unstructured":"Feng ST, Wang ZZ, Yuan YH, Sun HM, Chen NH, Zhang Y (2021) Update on the association between alpha-synuclein and tau with mitochondrial dysfunction: implications for Parkinson\u2019s disease. Eur J Neurosci 53:2946\u20132959. https:\/\/doi.org\/10.1111\/ejn.14699","journal-title":"Eur J Neurosci"},{"key":"10114_CR23","doi-asserted-by":"publisher","first-page":"105654","DOI":"10.1016\/j.nbd.2022.105654","volume":"166","author":"A Kasen","year":"2022","unstructured":"Kasen A, Houck C, Burmeister AR, Sha Q, Brundin L, Brundin P (2022) Upregulation of \u03b1-synuclein following immune activation: possible trigger of Parkinson\u2019s disease. Neurobiol Dis 166:105654. https:\/\/doi.org\/10.1016\/j.nbd.2022.105654","journal-title":"Neurobiol Dis"},{"key":"10114_CR24","doi-asserted-by":"publisher","first-page":"642900","DOI":"10.3389\/fphar.2021.642900","volume":"12","author":"L Chen","year":"2021","unstructured":"Chen L, Huang Y, Yu X, Lu J, Jia W, Song J, Liu L, Wang Y, Huang Y, Xie J, Li M (2021) Corynoxine protects dopaminergic neurons through inducing autophagy and diminishing neuroinflammation in rotenone-induced animal models of Parkinson\u2019s disease. Front Pharmacol 12:642900. https:\/\/doi.org\/10.3389\/fphar.2021.642900","journal-title":"Front Pharmacol"},{"key":"10114_CR25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mds.27633","volume":"34","author":"CH Lin","year":"2019","unstructured":"Lin CH, Chen PL, Tai CH, Lin HI, Chen CS, Chen ML, Wu RM (2019) A clinical and genetic study of early-onset and familial parkinsonism in taiwan: an integrated approach combining gene dosage analysis and next-generation sequencing. Mov Disord 34:506\u2013515. https:\/\/doi.org\/10.1002\/mds.27633","journal-title":"Mov Disord"},{"key":"10114_CR26","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/JAMANEUROL.2014.1909","volume":"71","author":"J Trinh","year":"2014","unstructured":"Trinh J, Guella I, Farrer MJ (2014) Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol 71:1535\u20131539. https:\/\/doi.org\/10.1001\/JAMANEUROL.2014.1909","journal-title":"JAMA Neurol"},{"key":"10114_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/S00441-017-2768-8\/FIGURES\/3","volume":"373","author":"SB Larsen","year":"2018","unstructured":"Larsen SB, Hanss Z, Kr\u00fcger R (2018) The genetic architecture of mitochondrial dysfunction in Parkinson\u2019s disease. Cell Tissue Res 373:21\u201337. https:\/\/doi.org\/10.1007\/S00441-017-2768-8\/FIGURES\/3","journal-title":"Cell Tissue Res"},{"key":"10114_CR28","doi-asserted-by":"publisher","unstructured":"Gialluisi A, Reccia MG, Modugno N, Nutile T, Lombardi A, Di Giovannantonio LG, Pietracupa S, Ruggiero D, Scala S, Gambardella S, Noyce AJ, Kaiyrzhanov R, Middlehurst B, Kia DA, Tan M, Houlden H, Morris HR, Plun-Favreau H, Holmans P, Hardy J, Trabzuni D, Quinn J, Bubb V, Mok KY, Kinghorn KJ, Billingsley K, Wood NW, Lewis P, Schreglmann S, Lovering R, R\u2019Bibo L, Manzoni C, Rizig M, Ryten M, Guelfi S, Escott-Price V, Chelban V, Foltynie T, Williams N, Morrison KE, Clarke C, Brice A, Danjou F, Lesage S, Corvol JC, Martinez M, Schulte C, Brockmann K, Sim\u00f3n-S\u00e1nchez J, Heutink P, Rizzu P, Sharma M, Gasser T, Cookson MR, Bandres-Ciga S, Blauwendraat C, Craig DW, Narendra D, Faghri F, Gibbs JR, Hernandez DG, Van Keuren-Jensen K, Shulman JM, Iwaki H, Leonard HL, Nalls MA, Robak L, Bras J, Guerreiro R, Lubbe S, Finkbeiner S, Mencacci NE, Lungu C, Singleton AB, Scholz SW, Reed X, Alcalay RN, Gan-Or Z, Rouleau GA, Krohn L, Krohn L, van Hilten JJ, Marinus J, Adarmes-G\u00f3mez AD, Aguilar M, Alvarez I, Alvarez V, Barrero FJ, Yarza JAB, Bernal-Bernal I, Blazquez M, Bonilla-Toribio M, Bot\u00eda JA, Boungiorno MT, Buiza-Rueda D, Carrillo F, Carri\u00f3n-Claro M, Cerdan D, Clarim\u00f3n J, Compta Y, Diez-Fairen M, Dols-Icardo O, Duarte J, Duran R, Escamilla-Sevilla F, Ezquerra M, Feliz C, Fern\u00e1ndez M, Fern\u00e1ndez-Santiago R, Garcia C, Garc\u00eda-Ruiz P, G\u00f3mez-Garre P, Heredia MJG, Gonzalez-Aramburu I, Pagola AG, Hoenicka J, Infante J, Jes\u00fas S, Jimenez-Escrig A, Kulisevsky J, Labrador-Espinosa MA, Lopez-Sendon JL, de Munain Arregui AL, Macias D, Torres IM, Mar\u00edn J, Marti MJ, Mart\u00ednez-Castrillo JC, M\u00e9ndez-del-Barrio C, Gonz\u00e1lez MM, Mata M, M\u00ednguez A, Mir P, Rezola EM, Mu\u00f1oz E, Pagonabarraga J, Pastor P, Errazquin FP, Peri\u00f1\u00e1n-Tocino T, Ruiz-Mart\u00ednez J, Ruz C, Rodriguez AS, Sierra M, Suarez-Sanmartin E, Tabernero C, Tartari JP, Tejera-Parrado C, Tolosa E, Valldeoriola F, Vargas-Gonz\u00e1lez L, Vela L, Vives F, Zimprich A, Pihlstrom L, Toft M, Koks S, Taba P, Hassin-Baer S, Majamaa K, Siitonen A, Okubadejo NU, Ojo OO, Kaiyrzhanov R, Shashkin C, Zharkynbekova N, Akhmetzhanov V, Aitkulova A, Zholdybayeva E, Zharmukhanov Z, Kaishybayeva G, Karimova A, Sadykova D, Iacoviello L, Gianfrancesco F, Acampora D, Esposito MD, Simeone A, Ciullo M, Esposito T (2021) Identification of sixteen novel candidate genes for late onset Parkinson\u2019s disease. Mol Neurodegener 16:1\u201318. https:\/\/doi.org\/10.1186\/S13024-021-00455-2\/FIGURES\/6","DOI":"10.1186\/S13024-021-00455-2\/FIGURES\/6"},{"key":"10114_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13024-023-00600-z","volume":"18","author":"A Haider","year":"2023","unstructured":"Haider A, Elghazawy NH, Dawood A, Gebhard C, Wichmann T, Sippl W, Hoener M, Arenas E, Liang SH (2023) Translational molecular imaging and drug development in Parkinson\u2019s disease. Mol Neurodegener 18:11. https:\/\/doi.org\/10.1186\/s13024-023-00600-z","journal-title":"Mol Neurodegener"},{"key":"10114_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-019-0165-9","volume":"8","author":"SYY Pang","year":"2019","unstructured":"Pang SYY, Ho PWL, Liu HF, Leung CT, Li L, Chang EES, Ramsden DB, Ho SL (2019) The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson\u2019s disease. Transl Neurodegener 8:1. https:\/\/doi.org\/10.1186\/s40035-019-0165-9","journal-title":"Transl Neurodegener"},{"key":"10114_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","volume":"15","author":"Y Hou","year":"2019","unstructured":"Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA (2019) Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15:565\u2013581. https:\/\/doi.org\/10.1038\/s41582-019-0244-7","journal-title":"Nat Rev Neurol"},{"key":"10114_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102044","author":"S Salvioli","year":"2023","unstructured":"Salvioli S, Basile MS, Bencivenga L, Carrino S, Conte M, Damanti S, De Lorenzo R, Fiorenzato E, Gialluisi A, Ingannato A, Antonini A, Baldini N, Capri M, Cenci S, Iacoviello L, Nacmias B, Olivieri F, Rengo G, Querini PR, Lattanzio F (2023) Biomarkers of aging in frailty and age-associated disorders: state of the art and future perspective. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2023.102044","journal-title":"Ageing Res Rev"},{"key":"10114_CR33","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK (2020) Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry 91:795\u2013808. https:\/\/doi.org\/10.1136\/jnnp-2019-322338","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10114_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.parkreldis.2020.06.018","volume":"77","author":"LJ Dommershuijsen","year":"2020","unstructured":"Dommershuijsen LJ, Heshmatollah A, Darweesh SKL, Koudstaal PJ, Ikram MA, Ikram MK (2020) Life expectancy of parkinsonism patients in the general population. Park Relat Disord 77:94\u201399. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.06.018","journal-title":"Park Relat Disord"},{"key":"10114_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27072366","volume":"27","author":"A Mori","year":"2022","unstructured":"Mori A, Chen JF, Uchida S, Durlach C, King SM, Jenner P (2022) The pharmacological potential of adenosine A2A receptor antagonists for treating Parkinson\u2019s disease. Molecules 27:2366. https:\/\/doi.org\/10.3390\/molecules27072366","journal-title":"Molecules"},{"key":"10114_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.602697","volume":"14","author":"X Ren","year":"2020","unstructured":"Ren X, Chen JF (2020) Caffeine and Parkinson\u2019s disease: multiple benefits and emerging mechanisms. Front Neurosci 14:602697. https:\/\/doi.org\/10.3389\/fnins.2020.602697","journal-title":"Front Neurosci"},{"key":"10114_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s43042-022-00354-1","volume":"23","author":"HM Al-kuraishy","year":"2022","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Elekhnawy E, Batiha GES (2022) Dipyridamole and adenosinergic pathway in COVID-19: a juice or holy grail. Egypt J Med Hum Genet 23:140. https:\/\/doi.org\/10.1186\/s43042-022-00354-1","journal-title":"Egypt J Med Hum Genet"},{"key":"10114_CR38","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-3-319-90808-3_2","volume":"34","author":"D Boison","year":"2018","unstructured":"Boison D (2018) Regulation of extracellular adenosine. Receptors 34:13\u201332. https:\/\/doi.org\/10.1007\/978-3-319-90808-3_2","journal-title":"Receptors"},{"key":"10114_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/cells9030785","volume":"9","author":"WI Effendi","year":"2020","unstructured":"Effendi WI, Nagano T, Kobayashi K, Nishimura Y (2020) Focusing on adenosine receptors as a potential targeted therapy in human diseases. Cells 9:785. https:\/\/doi.org\/10.3390\/cells9030785","journal-title":"Cells"},{"key":"10114_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-021-00766-y","volume":"28","author":"CP Chang","year":"2021","unstructured":"Chang CP, Wu KC, Lin CY, Chern Y (2021) Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases. J Biomed Sci 28:1\u201325. https:\/\/doi.org\/10.1186\/s12929-021-00766-y","journal-title":"J Biomed Sci"},{"key":"10114_CR41","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.bbamem.2010.05.021","volume":"1808","author":"H Piirainen","year":"2011","unstructured":"Piirainen H, Ashok Y, Nanekar RT, Jaakola VP (2011) Structural features of adenosine receptors: from crystal to function. Biochimica et Biophysica Acta (BBA) - Biomembranes 1808:1233\u20131244. https:\/\/doi.org\/10.1016\/j.bbamem.2010.05.021","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"key":"10114_CR42","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/NRD2638","volume":"7","author":"G Hask\u00f3","year":"2008","unstructured":"Hask\u00f3 G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759\u2013770. https:\/\/doi.org\/10.1038\/NRD2638","journal-title":"Nat Rev Drug Discov"},{"key":"10114_CR43","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.2174\/1381612825666190712181955","volume":"25","author":"H Choudhury","year":"2019","unstructured":"Choudhury H, Chellappan DK, Sengupta P, Pandey M, Gorain B (2019) Adenosine receptors in modulation of central nervous system disorders. Curr Pharm Des 25:2808\u20132827. https:\/\/doi.org\/10.2174\/1381612825666190712181955","journal-title":"Curr Pharm Des"},{"key":"10114_CR44","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/J.1365-201X.2007.01691.X","volume":"190","author":"NO Hermansson","year":"2007","unstructured":"Hermansson NO, Morgan DGA, Drmota T, Larsson N (2007) Adenosine is not a direct GHSR agonist--artificial cross-talk between GHSR and adenosine receptor pathways. Acta Physiol (Oxf) 190:77\u201386. https:\/\/doi.org\/10.1111\/J.1365-201X.2007.01691.X","journal-title":"Acta Physiol (Oxf)"},{"key":"10114_CR45","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/jcm9051366","volume":"9","author":"R Guieu","year":"2020","unstructured":"Guieu R, Deharo JC, Maille B, Crotti L, Torresani E, Brignole M, Parati G (2020) Adenosine and the cardiovascular system: the good and the bad. J Clin Med 9:1366. https:\/\/doi.org\/10.3390\/jcm9051366","journal-title":"J Clin Med"},{"key":"10114_CR46","doi-asserted-by":"publisher","first-page":"481.e1","DOI":"10.1016\/j.ajem.2020.11.009","volume":"44","author":"M Abbas","year":"2021","unstructured":"Abbas M, Verville J, Mroue K (2021) Resolution of bronchoconstriction with positive airway pressure after intravenous adenosine. Am J Emerg Med 44:481.e1-481.e2. https:\/\/doi.org\/10.1016\/j.ajem.2020.11.009","journal-title":"Am J Emerg Med"},{"key":"10114_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109329","volume":"223","author":"S Ferr\u00e9","year":"2023","unstructured":"Ferr\u00e9 S, Sarasola LI, Quiroz C, Ciruela F (2023) Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum. Neuropharmacology 223:109329. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109329","journal-title":"Neuropharmacology"},{"key":"10114_CR48","doi-asserted-by":"publisher","unstructured":"Peng W, Wu Z, Song K, Zhang S, Li Y, Xu M (2020) Regulation of sleep homeostasis mediator adenosine by basal forebrain glutamatergic neurons. Science 369. https:\/\/doi.org\/10.1126\/SCIENCE.ABB0556","DOI":"10.1126\/SCIENCE.ABB0556"},{"key":"10114_CR49","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/J.NBD.2009.10.023","volume":"37","author":"A Castillo","year":"2010","unstructured":"Castillo A, Tol\u00f3n MR, Fern\u00e1ndez-Ruiz J, Romero J, Martinez-Orgado J (2010) The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol Dis 37:434\u2013440. https:\/\/doi.org\/10.1016\/J.NBD.2009.10.023","journal-title":"Neurobiol Dis"},{"key":"10114_CR50","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/glia.23694","volume":"67","author":"R Franco","year":"2019","unstructured":"Franco R, Reyes-Resina I, Aguinaga D, Lillo A, Jim\u00e9nez J, Ra\u00efch I, Borroto-Escuela DO, Ferreiro-Vera C, Canela EI, de S\u00e1nchez Medina V, del Ser-Badia A, Fuxe K, Saura CA, Navarro G (2019) Potentiation of cannabinoid signaling in microglia by adenosine A2A receptor antagonists. Glia 67:2410\u20132423. https:\/\/doi.org\/10.1002\/glia.23694","journal-title":"Glia"},{"key":"10114_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/jnc.14841","volume":"151","author":"D van Calker","year":"2019","unstructured":"van Calker D, Biber K, Domschke K, Serchov T (2019) The role of adenosine receptors in mood and anxiety disorders. J Neurochem 151:11\u201327. https:\/\/doi.org\/10.1111\/jnc.14841","journal-title":"J Neurochem"},{"key":"10114_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228710","author":"F Vincenzi","year":"2020","unstructured":"Vincenzi F, Pasquini S, Borea PA, Varani K (2020) Targeting adenosine receptors: a potential pharmacological avenue for acute and chronic pain. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21228710","journal-title":"Int J Mol Sci"},{"key":"10114_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232214365","volume":"23","author":"L Goya","year":"2022","unstructured":"Goya L, Kongor JE, de Pascual-Teresa S (2022) From cocoa to chocolate: effect of processing on flavanols and methylxanthines and their mechanisms of action. Int J Mol Sci 23:14365. https:\/\/doi.org\/10.3390\/ijms232214365","journal-title":"Int J Mol Sci"},{"key":"10114_CR54","doi-asserted-by":"publisher","first-page":"145898","DOI":"10.1016\/J.SCITOTENV.2021.145898","volume":"775","author":"F L\u00f6her","year":"2021","unstructured":"L\u00f6her F, Palm WU, Schaffer M, Olsson O (2021) Concentrations and sources of methylxanthines in a Northern German river system. Sci Total Environ 775:145898. https:\/\/doi.org\/10.1016\/J.SCITOTENV.2021.145898","journal-title":"Sci Total Environ"},{"key":"10114_CR55","doi-asserted-by":"publisher","unstructured":"Przeor M, Beszterda M (2022) Coffee methylxanthines and human health effects. In:\u00a0Coffee Science: Biotechnological Advances, Economics, and Health Benefits.\u00a0CRC Press, pp 251\u2013263. https:\/\/doi.org\/10.1201\/9781003043133-24","DOI":"10.1201\/9781003043133-24"},{"key":"10114_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/JCDD10090400","author":"E Riguene","year":"2023","unstructured":"Riguene E, Theodoridou M, Barrak L, Elrayess MA, Nomikos M (2023) The relationship between changes in MYBPC3 single-nucleotide polymorphism-associated metabolites and elite athletes\u2019 adaptive cardiac function. J Cardiovasc Dev Dis. https:\/\/doi.org\/10.3390\/JCDD10090400","journal-title":"J Cardiovasc Dev Dis"},{"key":"10114_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S42269-022-00829-6","volume":"46","author":"H Ariffin","year":"2022","unstructured":"Ariffin H, Chong XQ, Chong PN, Okechukwu PN (2022) Is the consumption of energy drink beneficial or detrimental to health: a comprehensive review? Bull Natl Res Cent 46:1\u201328. https:\/\/doi.org\/10.1186\/S42269-022-00829-6","journal-title":"Bull Natl Res Cent"},{"key":"10114_CR58","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/978-3-642-13443-2_21","volume":"200","author":"MS Beaudoin","year":"2011","unstructured":"Beaudoin MS, Graham TE (2011) Methylxanthines and human health: epidemiological and experimental evidence. Handb Exp Pharmacol 200:509\u2013548. https:\/\/doi.org\/10.1007\/978-3-642-13443-2_21","journal-title":"Handb Exp Pharmacol"},{"key":"10114_CR59","doi-asserted-by":"publisher","first-page":"L197","DOI":"10.1152\/ajplung.00005.2018","volume":"316","author":"Y Bin","year":"2019","unstructured":"Bin Y, Xiao Y, Huang D, Ma Z, Liang Y, Bai J, Zhang W, Liang Q, Zhang J, Zhong X, He Z (2019) Theophylline inhibits cigarette smoke-induced inflammation in skeletal muscle by upregulating hdac2 expression and decreasing nf-\u03bab activation. Am J Physiol-Lung Cell Mol Physiol 316:L197\u2013L205. https:\/\/doi.org\/10.1152\/ajplung.00005.2018","journal-title":"Am J Physiol-Lung Cell Mol Physiol"},{"key":"10114_CR60","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1080\/10408398.2018.1461607","volume":"59","author":"J Monteiro","year":"2019","unstructured":"Monteiro J, Alves MG, Oliveira PF, Silva BM (2019) Pharmacological potential of methylxanthines: retrospective analysis and future expectations. Crit Rev Food Sci Nutr 59:2597\u20132625. https:\/\/doi.org\/10.1080\/10408398.2018.1461607","journal-title":"Crit Rev Food Sci Nutr"},{"key":"10114_CR61","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1136\/bjo-2021-320920","volume":"107","author":"K Trier","year":"2022","unstructured":"Trier K, Cui D, Ribel-Madsen S, Guggenheim J (2022) Oral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish children. Br J Ophthalmol 107:1538\u20131544. https:\/\/doi.org\/10.1136\/bjo-2021-320920","journal-title":"Br J Ophthalmol"},{"key":"10114_CR62","doi-asserted-by":"publisher","first-page":"9752366","DOI":"10.31838\/ijpr\/2022.14.04.003","volume":"14","author":"R Yadav","year":"2022","unstructured":"Yadav R, Sharma R, Chawla A (2022) Diuretic effect of Xanthine derivatives: a critical review. Int J Pharm Res 14:9752366. https:\/\/doi.org\/10.31838\/ijpr\/2022.14.04.003","journal-title":"Int J Pharm Res"},{"key":"10114_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2019.101851","volume":"59","author":"M Talmon","year":"2019","unstructured":"Talmon M, Massara E, Brunini C, Fresu LG (2019) Comparison of anti-inflammatory mechanisms between doxofylline and theophylline in human monocytes. Pulm Pharmacol Ther 59:101851. https:\/\/doi.org\/10.1016\/j.pupt.2019.101851","journal-title":"Pulm Pharmacol Ther"},{"key":"10114_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.840710","volume":"10","author":"K Abduljalil","year":"2022","unstructured":"Abduljalil K, Gardner I, Jamei M (2022) Application of a physiologically based pharmacokinetic approach to predict theophylline pharmacokinetics using virtual non-pregnant, pregnant, fetal, breast-feeding, and neonatal populations. Front Pediatr 10:840710. https:\/\/doi.org\/10.3389\/fped.2022.840710","journal-title":"Front Pediatr"},{"key":"10114_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/nu13030803","author":"D Janitschke","year":"2021","unstructured":"Janitschke D, Lauer AA, Bachmann CM, Grimm HS, Hartmann T, Grimm MOW (2021) Methylxanthines and neurodegenerative diseases: an update. Nutrients. https:\/\/doi.org\/10.3390\/nu13030803","journal-title":"Nutrients"},{"key":"10114_CR66","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11064-022-03817-4","volume":"48","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Alsayegh AA, Hakami ZH, Khamjan NA, Saad HM, Batiha GES, De Waard M (2023) A potential link between visceral obesity and risk of Alzheimer\u2019s disease. Neurochem Res 48:745\u2013766. https:\/\/doi.org\/10.1007\/s11064-022-03817-4","journal-title":"Neurochem Res"},{"key":"10114_CR67","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10787-023-01163-7","volume":"31","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GES (2023) Long-term use of metformin and Alzheimer\u2019s disease: beneficial or detrimental effects. Inflammopharmacology 31:1107\u20131115. https:\/\/doi.org\/10.1007\/s10787-023-01163-7","journal-title":"Inflammopharmacology"},{"key":"10114_CR68","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10787-022-01099-4","volume":"31","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GES (2023) Benzodiazepines in Alzheimer\u2019s disease: beneficial or detrimental effects. Inflammopharmacology 31:221\u2013230. https:\/\/doi.org\/10.1007\/s10787-022-01099-4","journal-title":"Inflammopharmacology"},{"key":"10114_CR69","doi-asserted-by":"publisher","unstructured":"Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, Khalifa AA, Saad HM, Batiha GES (2024) Neprilysin inhibitors and risk of Alzheimer\u2019s disease: a future perspective. J Cell Mol Med 28. https:\/\/doi.org\/10.1111\/jcmm.17993","DOI":"10.1111\/jcmm.17993"},{"key":"10114_CR70","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s13760-023-02403-x","volume":"124","author":"NH Ali","year":"2024","unstructured":"Ali NH, Al-kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, Saad HM, Batiha GES (2024) The probable role of tissue plasminogen activator\/neuroserpin axis in Alzheimer\u2019s disease: a new perspective. Acta Neurol Belg 124:377\u2013388. https:\/\/doi.org\/10.1007\/s13760-023-02403-x","journal-title":"Acta Neurol Belg"},{"key":"10114_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12101290","volume":"12","author":"N Alsubaie","year":"2022","unstructured":"Alsubaie N, Al-kuraishy HM, Al-Gareeb AI, Alharbi B, De Waard M, Sabatier JM, Saad HM, Batiha GES (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12:1290. https:\/\/doi.org\/10.3390\/brainsci12101290","journal-title":"Brain Sci"},{"key":"10114_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01082-1","volume":"15","author":"M Alrouji","year":"2023","unstructured":"Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Saad HM, Batiha GES (2023) The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer\u2019s diseases. Diabetol Metab Syndr 15:101. https:\/\/doi.org\/10.1186\/s13098-023-01082-1","journal-title":"Diabetol Metab Syndr"},{"key":"10114_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102119","author":"HM Al-kuraishy","year":"2023","unstructured":"Al-kuraishy HM, Jabir MS, Al-Gareeb AI, Albuhadily AK, Albukhaty S, Sulaiman GM, Batiha GES (2023) Evaluation and targeting of amyloid precursor protein (APP)\/amyloid beta (A\u03b2) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel. Ageing Res Rev. https:\/\/doi.org\/10.1016\/j.arr.2023.102119","journal-title":"Ageing Res Rev"},{"key":"10114_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/cells10092344","volume":"10","author":"S Gessi","year":"2021","unstructured":"Gessi S, Poloni TE, Negro G, Varani K, Pasquini S, Vincenzi F, Borea PA, Merighi S (2021) A2a adenosine receptor as a potential biomarker and a possible therapeutic target in Alzheimer\u2019s disease. Cells 10:2344. https:\/\/doi.org\/10.3390\/cells10092344","journal-title":"Cells"},{"key":"10114_CR75","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3892\/ijmm.2018.3935","volume":"43","author":"Z Liu","year":"2019","unstructured":"Liu Z, Wang F, Tang M, Zhao Y, Wang X (2019) Amyloid \u03b2 and tau are involved in sleep disorder in Alzheimer\u2019s disease by orexin A and adenosine A(1) receptor. Int J Mol Med 43:435\u2013442. https:\/\/doi.org\/10.3892\/ijmm.2018.3935","journal-title":"Int J Mol Med"},{"key":"10114_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2022.147944","volume":"1788","author":"M Zeng","year":"2022","unstructured":"Zeng M, Feng A, Zhao C, Zhang B, Guo P, Liu M, Zhang Q, Zhang Y, Fan R, Lyu J, Zheng X (2022) Adenosine ameliorated A\u03b225\u221235-induced brain injury through the inhibition of apoptosis and oxidative stress via an ER\u03b1 pathway. Brain Res 1788:147944. https:\/\/doi.org\/10.1016\/j.brainres.2022.147944","journal-title":"Brain Res"},{"key":"10114_CR77","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11302-022-09883-1","volume":"18","author":"PNH Trinh","year":"2022","unstructured":"Trinh PNH, Baltos JA, Hellyer SD, May LT, Gregory KJ (2022) Adenosine receptor signalling in Alzheimer\u2019s disease. Purinergic Signal 18:359\u2013381. https:\/\/doi.org\/10.1007\/s11302-022-09883-1","journal-title":"Purinergic Signal"},{"key":"10114_CR78","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/pharmrev.121.000445","volume":"74","author":"AP Ijzerman","year":"2022","unstructured":"Ijzerman AP, Jacobson KA, M\u00fcller CE, Cronstein BN, Cunha RA (2022) International union of basic and clinical pharmacology. CXII: adenosine receptors: a further update. Pharmacol Rev 74:340\u2013372. https:\/\/doi.org\/10.1124\/pharmrev.121.000445","journal-title":"Pharmacol Rev"},{"key":"10114_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.735933","volume":"13","author":"A Razazan","year":"2021","unstructured":"Razazan A, Karunakar P, Mishra SP, Sharma S, Miller B, Jain S, Yadav H (2021) Activation of microbiota sensing \u2013 free fatty acid receptor 2 signaling ameliorates amyloid-\u03b2 induced neurotoxicity by modulating proteolysis-senescence axis. Front Aging Neurosci 13:735933. https:\/\/doi.org\/10.3389\/fnagi.2021.735933","journal-title":"Front Aging Neurosci"},{"key":"10114_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051242","volume":"9","author":"F Vincenzi","year":"2020","unstructured":"Vincenzi F, Pasquini S, Gessi S, Merighi S, Romagnoli R, Borea PA, Varani K (2020) The detrimental action of adenosine on glutamate-induced cytotoxicity in PC12 cells can be shifted towards a neuroprotective role through A1AR positive allosteric modulation. Cells 9:1242. https:\/\/doi.org\/10.3390\/cells9051242","journal-title":"Cells"},{"key":"10114_CR81","doi-asserted-by":"publisher","first-page":"10500","DOI":"10.1002\/jcp.27719","volume":"234","author":"FP Arasi","year":"2019","unstructured":"Arasi FP, Shahrestanaki MK, Aghaei M (2019) A2a adenosine receptor agonist improves endoplasmic reticulum stress in MIN6 cell line through protein kinase A\/ protein kinase B\/ cyclic adenosine monophosphate response element-binding protein\/ and Growth Arrest And DNA-Damage-Inducible 34\/ eukaryotic I. J Cell Physiol 234:10500\u201310511. https:\/\/doi.org\/10.1002\/jcp.27719","journal-title":"J Cell Physiol"},{"key":"10114_CR82","doi-asserted-by":"publisher","first-page":"105043","DOI":"10.1016\/j.nbd.2020.105043","volume":"145","author":"C Miranda-Louren\u00e7o","year":"2020","unstructured":"Miranda-Louren\u00e7o C, Duarte ST, Palminha C, Gaspar C, Rodrigues TM, Magalh\u00e3es-Cardosof T, Rei N, Colino-Oliveira M, Gomes R, Ferreira S, Rosa J, Xapelli S, Armstrong J, Garc\u00eda-Cazorla \u00c0, Correia-de-S\u00e1 P, Sebasti\u00e3o AM, Di\u00f3genes MJ (2020) Impairment of adenosinergic system in Rett syndrome: novel therapeutic target to boost BDNF signalling. Neurobiol Dis 145:105043. https:\/\/doi.org\/10.1016\/j.nbd.2020.105043","journal-title":"Neurobiol Dis"},{"key":"10114_CR83","doi-asserted-by":"publisher","first-page":"110288","DOI":"10.1016\/j.cbi.2022.110288","volume":"369","author":"MA Rabie","year":"2023","unstructured":"Rabie MA, Ibrahim HI, Nassar NN, Atef RM (2023) Adenosine A1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington\u2019s disease via stimulation of TrKB\/PI3K\/Akt\/CREB\/BDNF pathway in 3-nitropropionic acid rat model. Chem Biol Interact 369:110288. https:\/\/doi.org\/10.1016\/j.cbi.2022.110288","journal-title":"Chem Biol Interact"},{"key":"10114_CR84","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s11064-023-04064-x","volume":"49","author":"R AlRuwaili","year":"2024","unstructured":"AlRuwaili R, Al-kuraishy HM, Al-Gareeb AI, Ali NH, Alexiou A, Papadakis M, Saad HM, Batiha GES (2024) The possible role of brain-derived neurotrophic factor in epilepsy. Neurochem Res 49:533\u2013547. https:\/\/doi.org\/10.1007\/s11064-023-04064-x","journal-title":"Neurochem Res"},{"key":"10114_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0604-5","volume":"9","author":"JW Kim","year":"2019","unstructured":"Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Jung G, Lee HN, Sohn BK, Lee JY, Kim YK, Shin SA, Sohn CH, Lee DY (2019) Coffee intake and decreased amyloid pathology in human brain. Transl Psychiatry 9:9. https:\/\/doi.org\/10.1038\/s41398-019-0604-5","journal-title":"Transl Psychiatry"},{"key":"10114_CR86","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3233\/JAD-2009-1087","volume":"17","author":"GW Arendash","year":"2009","unstructured":"Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tan J, Citron BA, Lin X, Echeverria V, Potter H (2009) Caffeine reverses cognitive impairment and decreases brain amyloid-\u03b2 levels in aged Alzheimer\u2019s disease mice. J Alzheimers Dis 17:661\u2013680. https:\/\/doi.org\/10.3233\/JAD-2009-1087","journal-title":"J Alzheimers Dis"},{"key":"10114_CR87","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3233\/JAD-2009-1071","volume":"17","author":"C Cao","year":"2009","unstructured":"Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, Holtzman DM, Potter H (2009) Caffeine suppresses amyloid-\u03b2 levels in plasma and brain of Alzheimer\u2019s disease transgenic mice. J Alzheimers Dis 17:681\u2013697. https:\/\/doi.org\/10.3233\/JAD-2009-1071","journal-title":"J Alzheimers Dis"},{"key":"10114_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu13020537","volume":"13","author":"P Londzin","year":"2021","unstructured":"Londzin P, Zamora M, K\u0105kol B, Taborek A, Folwarczna J (2021) Potential of caffeine in Alzheimer\u2019s disease\u2014a review of experimental studies. Nutrients 13:1\u201333. https:\/\/doi.org\/10.3390\/nu13020537","journal-title":"Nutrients"},{"key":"10114_CR89","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1046\/j.1468-1331.2002.00421.x","volume":"9","author":"L Maia","year":"2002","unstructured":"Maia L, De Mendon\u00e7a A (2002) Does caffeine intake protect from Alzheimer\u2019s disease? Eur J Neurol 9:377\u2013382. https:\/\/doi.org\/10.1046\/j.1468-1331.2002.00421.x","journal-title":"Eur J Neurol"},{"key":"10114_CR90","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3233\/JAD-150374","volume":"47","author":"M Travassos","year":"2015","unstructured":"Travassos M, Santana I, Baldeiras I, Tsolaki M, Gkatzima O, Genc S, Yener GG, Simonsen A, Hasselbalch SG, Kapaki E, Bourbouli M, Cunha RA, Agostinho P, Blennow K, Zetterberg H, Mendes VM, Manadas B, De Mendon\u00e7a A (2015) Does caffeine consumption modify cerebrospinal fluid amyloid-\u03b2 levels in patients with Alzheimer\u2019s disease? J Alzheimers Dis 47:1069\u20131078. https:\/\/doi.org\/10.3233\/JAD-150374","journal-title":"J Alzheimers Dis"},{"key":"10114_CR91","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.3233\/JAD-2010-091387","volume":"20","author":"C Santos","year":"2010","unstructured":"Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N (2010) Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis 20:S187-204. https:\/\/doi.org\/10.3233\/JAD-2010-091387","journal-title":"J Alzheimers Dis"},{"key":"10114_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/nu10101501","author":"SC Larsson","year":"2018","unstructured":"Larsson SC, Orsini N (2018) Coffee consumption and risk of dementia and Alzheimer\u2019s disease: a dose-response meta-analysis of prospective studies. Nutrients. https:\/\/doi.org\/10.3390\/nu10101501","journal-title":"Nutrients"},{"key":"10114_CR93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/ADR-200191","volume":"4","author":"O Sanders","year":"2020","unstructured":"Sanders O, Rajagopal L (2020) Phosphodiesterase inhibitors for Alzheimer\u2019s disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J Alzheimer\u2019s Dis Reports 4:185\u2013215. https:\/\/doi.org\/10.3233\/ADR-200191","journal-title":"J Alzheimer\u2019s Dis Reports"},{"key":"10114_CR94","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0197-0186(03)00006-8","volume":"43","author":"NB Chauhan","year":"2003","unstructured":"Chauhan NB, Siegel GJ (2003) Effect of PPF and ALCAR on the induction of NGF- and p75-mRNA and on APP processing in Tg2576 brain. Neurochem Int 43:225\u2013233. https:\/\/doi.org\/10.1016\/S0197-0186(03)00006-8","journal-title":"Neurochem Int"},{"key":"10114_CR95","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/15548627.2023.2259281","volume":"20","author":"HM Al-kuraishy","year":"2024","unstructured":"Al-kuraishy HM, Jabir MS, Al-Gareeb AI, Saad HM, Batiha GES, Klionsky DJ (2024) The beneficial role of autophagy in multiple sclerosis: yes or no? Autophagy 20:259\u2013274. https:\/\/doi.org\/10.1080\/15548627.2023.2259281","journal-title":"Autophagy"},{"key":"10114_CR96","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s10787-023-01240-x","volume":"31","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GES (2023) The potential therapeutic effect of statins in multiple sclerosis: beneficial or detrimental effects. Inflammopharmacology 31:1671\u20131682. https:\/\/doi.org\/10.1007\/s10787-023-01240-x","journal-title":"Inflammopharmacology"},{"key":"10114_CR97","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1007\/s11064-023-03981-1","volume":"48","author":"M Alruwaili","year":"2023","unstructured":"Alruwaili M, Al-kuraishy HM, Alexiou A, Papadakis M, ALRashdi BM, Elhussieny O, Saad HM, Batiha GES (2023) Pathogenic role of fibrinogen in the neuropathology of multiple sclerosis: a tale of sorrows and fears. Neurochem Res 48:3255\u20133269. https:\/\/doi.org\/10.1007\/s11064-023-03981-1","journal-title":"Neurochem Res"},{"key":"10114_CR98","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00011-016-0936-z","volume":"65","author":"E Safarzadeh","year":"2016","unstructured":"Safarzadeh E, Jadidi-Niaragh F, Motallebnezhad M, Yousefi M (2016) The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis. Inflamm Res 65:511\u2013520. https:\/\/doi.org\/10.1007\/s00011-016-0936-z","journal-title":"Inflamm Res"},{"key":"10114_CR99","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1523\/JNEUROSCI.4271-03.2004","volume":"24","author":"S Tsutsui","year":"2004","unstructured":"Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, Warren K, Power C (2004) A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 24:1521\u20131529. https:\/\/doi.org\/10.1523\/JNEUROSCI.4271-03.2004","journal-title":"J Neurosci"},{"key":"10114_CR100","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/ana.1007","volume":"49","author":"JB Johnston","year":"2001","unstructured":"Johnston JB, Silva C, Gonzalez G, Holden J, Warren KG, Metz LM, Power C (2001) Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol 49:650\u2013658. https:\/\/doi.org\/10.1002\/ana.1007","journal-title":"Ann Neurol"},{"key":"10114_CR101","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/jcbfm.2013.85","volume":"33","author":"E Rissanen","year":"2013","unstructured":"Rissanen E, Virta JR, Paavilainen T, Tuisku J, Helin S, Luoto P, Parkkola R, Rinne JO, Airas L (2013) Adenosine A2A receptors in secondary progressive multiple sclerosis: a [ 11 C]TMSX brain PET study. J Cereb Blood Flow Metab 33:1394\u20131401. https:\/\/doi.org\/10.1038\/jcbfm.2013.85","journal-title":"J Cereb Blood Flow Metab"},{"key":"10114_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.998023","author":"B Kutryb-Zajac","year":"2022","unstructured":"Kutryb-Zajac B, Kawecka A, Caratis F, Urbanowicz K, Braczko A, Furihata T, Karaszewski B, Smolenski RT, Rutkowska A (2022) The impaired distribution of adenosine deaminase isoenzymes in multiple sclerosis plasma and cerebrospinal fluid. Front Mol Neurosci. https:\/\/doi.org\/10.3389\/fnmol.2022.998023","journal-title":"Front Mol Neurosci"},{"key":"10114_CR103","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fnut.2018.00133","volume":"5","author":"L Herden","year":"2018","unstructured":"Herden L, Weissert R (2018) The impact of coffee and caffeine on multiple sclerosis compared to other neurodegenerative diseases. Front Nutr 5:133. https:\/\/doi.org\/10.3389\/fnut.2018.00133","journal-title":"Front Nutr"},{"key":"10114_CR104","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03596.x","author":"MB D\u2019hooghe","year":"2012","unstructured":"D\u2019hooghe MB, Haentjens P, Nagels G, De Keyser J (2012) Alcohol, coffee, fish, smoking and disease progression in multiple sclerosis. Eur J Neurol. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03596.x","journal-title":"Eur J Neurol"},{"key":"10114_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu12082262","volume":"12","author":"L Herden","year":"2020","unstructured":"Herden L, Weissert R (2020) The effect of coffee and caffeine consumption on patients with multiple sclerosis-related fatigue. Nutrients 12:1\u201313. https:\/\/doi.org\/10.3390\/nu12082262","journal-title":"Nutrients"},{"key":"10114_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2009.10.054","author":"GQ Chen","year":"2010","unstructured":"Chen GQ, Chen YY, Wang XS, Wu SZ, Yang HM, Xu HQ, He JC, Wang XT, Chen JF, Zheng RY (2010) Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Res. https:\/\/doi.org\/10.1016\/j.brainres.2009.10.054","journal-title":"Brain Res"},{"key":"10114_CR107","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17243-z","author":"M Duman","year":"2020","unstructured":"Duman M, Vaqui\u00e9 A, Nocera G, Heller M, Stumpe M, Siva Sankar D, Dengjel J, Meijer D, Yamaguchi T, Matthias P, Zeis T, Schaeren-Wiemers N, Hayoz A, Ruff S, Jacob C (2020) EEF1A1 deacetylation enables transcriptional activation of remyelination. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-020-17243-z","journal-title":"Nat Commun"},{"key":"10114_CR108","doi-asserted-by":"publisher","DOI":"10.3390\/cells9041037","author":"LM Ruiz-Perera","year":"2020","unstructured":"Ruiz-Perera LM, Greiner JFW, Kaltschmidt C, Kaltschmidt B (2020) A matter of choice: inhibition of c-rel shifts neuronal to oligodendroglial fate in human stem cells. Cells. https:\/\/doi.org\/10.3390\/cells9041037","journal-title":"Cells"},{"key":"10114_CR109","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S1474-4422(21)00465-8","volume":"21","author":"SA Goutman","year":"2022","unstructured":"Goutman SA, Hardiman O, Al-Chalabi A, Chi\u00f3 A, Savelieff MG, Kiernan MC, Feldman EL (2022) Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol 21:480\u2013493. https:\/\/doi.org\/10.1016\/S1474-4422(21)00465-8","journal-title":"Lancet Neurol"},{"key":"10114_CR110","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1111\/ene.14393","volume":"27","author":"P Masrori","year":"2020","unstructured":"Masrori P, Van Damme P (2020) Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 27:1918\u20131929. https:\/\/doi.org\/10.1111\/ene.14393","journal-title":"Eur J Neurol"},{"key":"10114_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9081027","author":"A Mori","year":"2021","unstructured":"Mori A, Cross B, Uchida S, Kerrick Walker J, Ristuccia R (2021) How are adenosine and adenosine a2a receptors involved in the pathophysiology of amyotrophic lateral sclerosis? Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines9081027","journal-title":"Biomedicines"},{"key":"10114_CR112","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/brain\/awy353","volume":"142","author":"SP Allen","year":"2019","unstructured":"Allen SP, Hall B, Castelli LM, Francis L, Woof R, Siskos AP, Kouloura E, Gray E, Thompson AG, Talbot K, Higginbottom A, Myszczynska M, Allen CF, Stopford MJ, Hemingway J, Bauer CS, Webster CP, De Vos KJ, Turner MR, Keun HC, Hautbergue GM, Ferraiuolo L, Shaw PJ (2019) Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain 142:586\u2013605. https:\/\/doi.org\/10.1093\/brain\/awy353","journal-title":"Brain"},{"key":"10114_CR113","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.expneurol.2015.03.004","volume":"267","author":"S kah Ng","year":"2015","unstructured":"kah Ng S, Higashimori H, Tolman M, Yang Y (2015) Suppression of adenosine 2a receptor (A2aR)-mediated adenosine signaling improves disease phenotypes in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 267:115\u2013122. https:\/\/doi.org\/10.1016\/j.expneurol.2015.03.004","journal-title":"Exp Neurol"},{"key":"10114_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-021-02288-4","volume":"21","author":"T Nukui","year":"2021","unstructured":"Nukui T, Matsui A, Niimi H, Sugimoto T, Hayashi T, Dougu N, Konishi H, Yamamoto M, Anada R, Matsuda N, Kitajima I, Nakatsuji Y (2021) Increased cerebrospinal fluid adenosine 5\u2019-triphosphate in patients with amyotrophic lateral sclerosis. BMC Neurol 21:1\u20138. https:\/\/doi.org\/10.1186\/s12883-021-02288-4","journal-title":"BMC Neurol"},{"key":"10114_CR115","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1089\/caff.2019.0016","volume":"9","author":"Y Chern","year":"2019","unstructured":"Chern Y, Rei N, Ribeiro JA, Sebasti\u00e3o AM (2019) Adenosine and its receptors as potential drug targets in amyotrophic lateral sclerosis. J Caffeine Adenosine Res 9:157\u2013166. https:\/\/doi.org\/10.1089\/caff.2019.0016","journal-title":"J Caffeine Adenosine Res"},{"key":"10114_CR116","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.23185","author":"RL Potenza","year":"2013","unstructured":"Potenza RL, Armida M, Ferrante A, P\u00e8zzola A, Matteucci A, Puopolo M, Popoli P (2013) Effects of chronic caffeine intake in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res. https:\/\/doi.org\/10.1002\/jnr.23185","journal-title":"J Neurosci Res"},{"key":"10114_CR117","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/EDE.0b013e3181632c5d","volume":"19","author":"N Morozova","year":"2008","unstructured":"Morozova N, Weisskopf MG, McCullough ML, Munger KL, Calle EE, Thun MJ, Ascherio A (2008) Diet and amyotrophic lateral sclerosis. Epidemiology 19:324\u2013337. https:\/\/doi.org\/10.1097\/EDE.0b013e3181632c5d","journal-title":"Epidemiology"},{"key":"10114_CR118","doi-asserted-by":"publisher","unstructured":"Beghi E, Pupillo E, Messina P, Giussani G, Chi\u00f2 A, Zoccolella S, Moglia C, Corbo M, Logroscino G, and the EURALS Group\u00a0(2011) Coffee and amyotrophic lateral sclerosis: a possible preventive role.\u00a0Am J Epidemiol 174:1002\u20131008. https:\/\/doi.org\/10.1093\/aje\/kwr229","DOI":"10.1093\/aje\/kwr229"},{"key":"10114_CR119","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3109\/21678421.2015.1020813","volume":"16","author":"E Fondell","year":"2015","unstructured":"Fondell E, Oreilly \u00c9J, Fitzgerald KC, Falcone GJ, Kolonel LN, Park Y, Gapstur SM, Ascherio A (2015) Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: results from five cohort studies. Amyotroph Lateral Scler Front Degener 16:366\u2013371. https:\/\/doi.org\/10.3109\/21678421.2015.1020813","journal-title":"Amyotroph Lateral Scler Front Degener"},{"key":"10114_CR120","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272104","author":"N Rei","year":"2022","unstructured":"Rei N, Valente CA, Vaz SH, Farinha-Ferreira M, Ribeiro JA, Sebasti\u00e3o AM (2022) Changes in adenosine receptors and neurotrophic factors in the SOD1G93A mouse model of amyotrophic lateral sclerosis: modulation by chronic caffeine. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0272104","journal-title":"PLoS ONE"},{"key":"10114_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106341","volume":"188","author":"R Rivas-Santisteban","year":"2023","unstructured":"Rivas-Santisteban R, Rico AJ, Mu\u00f1oz A, Rodr\u00edguez-P\u00e9rez AI, Reyes-Resina I, Navarro G, Labandeira-Garc\u00eda JL, Lanciego JL, Franco R (2023) Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson\u2019s disease. Neurobiol Dis 188:106341. https:\/\/doi.org\/10.1016\/j.nbd.2023.106341","journal-title":"Neurobiol Dis"},{"key":"10114_CR122","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.parkreldis.2020.09.027","volume":"80","author":"BB Fredholm","year":"2020","unstructured":"Fredholm BB, Svenningsson P (2020) Why target brain adenosine receptors? A historical perspective. Parkinsonism Relat Disord 80:S3\u2013S6. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.09.027","journal-title":"Parkinsonism Relat Disord"},{"key":"10114_CR123","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1254\/jphs.13250FP","volume":"124","author":"SI Uchida","year":"2014","unstructured":"Uchida SI, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T (2014) The adenosine A2A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. J Pharmacol Sci 124:480\u2013485. https:\/\/doi.org\/10.1254\/jphs.13250FP","journal-title":"J Pharmacol Sci"},{"key":"10114_CR124","doi-asserted-by":"publisher","unstructured":"Gomez-Castro F, Zappettini S, Pressey JC, Silva CG, Russeau M, Gervasi N, Figueiredo M, Montmasson C, Renner M, Canas PM, Gon\u00e7alves FQ, Al\u00e7ada-Morais S, Szab E, Rodrigues RJ, Agostinho P, Tom AR, Caillol G, Thoumine O, Nicol X, Leterrier C, Lujan R, Tyagarajan SK, Cunha RA, Esclapez M, Bernard C, L\u00e9vi S (2021) Convergence of adenosine and GABA signaling for synapse stabilization during development. Science 374. https:\/\/doi.org\/10.1126\/science.abk2055","DOI":"10.1126\/science.abk2055"},{"key":"10114_CR125","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1212\/WNL.0b013e31821ccce4","volume":"76","author":"AF Ramlackhansingh","year":"2011","unstructured":"Ramlackhansingh AF, Bose SK, Ahmed I, Turkheimer FE, Pavese N, Brooks DJ (2011) Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology 76:1811\u20131816. https:\/\/doi.org\/10.1212\/WNL.0b013e31821ccce4","journal-title":"Neurology"},{"key":"10114_CR126","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/brain\/awh128","volume":"127","author":"F Calon","year":"2004","unstructured":"Calon F, Dridi M, Hornykiewicz O, B\u00e9dard PJ, Rajput AH, Di Paolo T (2004) Increased adenosine A2A receptors in the brain of Parkinson\u2019s disease patients with dyskinesias. Brain 127:1075\u20131084. https:\/\/doi.org\/10.1093\/brain\/awh128","journal-title":"Brain"},{"key":"10114_CR127","doi-asserted-by":"publisher","first-page":"e17338","DOI":"10.1371\/journal.pone.0017338","volume":"6","author":"M Mishina","year":"2011","unstructured":"Mishina M, Ishiwata K, Naganawa M, Kimura Y, Kitamura S, Suzuki M, Hashimoto M, Ishibashi K, Oda K, Sakata M, Hamamoto M, Kobayashi S, Katayama Y, Ishii K (2011) Adenosine A2A receptors measured with [11C]TMSX pet in the striata of parkinson\u2019s disease patients. PLoS ONE 6:e17338. https:\/\/doi.org\/10.1371\/journal.pone.0017338","journal-title":"PLoS ONE"},{"key":"10114_CR128","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.cjtee.2023.08.003","volume":"27","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Zhou YG, Chen JF (2024) Targeting the adenosine A2A receptor for neuroprotection and cognitive improvement in traumatic brain injury and Parkinson\u2019s disease. Chin J Traumatol-Engl Ed 27:125\u2013133. https:\/\/doi.org\/10.1016\/j.cjtee.2023.08.003","journal-title":"Chin J Traumatol-Engl Ed"},{"key":"10114_CR129","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.parkreldis.2020.09.025","volume":"80","author":"A Mori","year":"2020","unstructured":"Mori A (2020) How do adenosine A2A receptors regulate motor function? Parkinsonism Relat Disord 80:S13\u2013S20. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.09.025","journal-title":"Parkinsonism Relat Disord"},{"key":"10114_CR130","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1111\/bph.14771","volume":"176","author":"M Carmo","year":"2019","unstructured":"Carmo M, Gon\u00e7alves FQ, Canas PM, Oses JP, Fernandes FD, Duarte FV, Palmeira CM, Tom\u00e9 AR, Agostinho P, Andrade GM, Cunha RA (2019) Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A2A receptor over-activation in a rat model of Parkinson\u2019s disease. Br J Pharmacol 176:3666\u20133680. https:\/\/doi.org\/10.1111\/bph.14771","journal-title":"Br J Pharmacol"},{"key":"10114_CR131","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1096\/fj.09-141044","volume":"24","author":"K Varani","year":"2010","unstructured":"Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P, Leung E, MacLennan S, Granieri E, Borea PA (2010) A 2A adenosine receptor overexpression and functionality, as well as TNF-\u03b1 levels, correlate with motor symptoms in Parkinson\u2019s disease. FASEB J 24:587\u2013598. https:\/\/doi.org\/10.1096\/fj.09-141044","journal-title":"FASEB J"},{"key":"10114_CR132","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","volume":"4","author":"M Cie\u015blak","year":"2008","unstructured":"Cie\u015blak M, Komoszy\u0144ski M, Wojtczak A (2008) Adenosine A2A receptors in Parkinson\u2019s disease treatment. Purinergic Signal 4:305\u2013312. https:\/\/doi.org\/10.1007\/s11302-008-9100-8","journal-title":"Purinergic Signal"},{"key":"10114_CR133","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/cercor\/bhv268","volume":"27","author":"DG Ferreira","year":"2017","unstructured":"Ferreira DG, Batalha VL, Miranda HV, Coelho JE, Gomes R, Gon\u00e7alves FQ, Real JI, Rino J, Albino-Teixeira A, Cunha RA, Outeiro TF, Lopes LV (2017) Adenosine A2A receptors modulate \u03b1-synuclein aggregation and toxicity. Cereb Cortex 27:718\u2013730. https:\/\/doi.org\/10.1093\/cercor\/bhv268","journal-title":"Cereb Cortex"},{"key":"10114_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00284-3","volume":"11","author":"E Jakova","year":"2022","unstructured":"Jakova E, Moutaoufik MT, Lee JS, Babu M, Cayabyab FS (2022) Adenosine A1 receptor ligands bind to \u03b1-synuclein: implications for \u03b1-synuclein misfolding and \u03b1-synucleinopathy in Parkinson\u2019s disease. Transl Neurodegener 11:9. https:\/\/doi.org\/10.1186\/s40035-022-00284-3","journal-title":"Transl Neurodegener"},{"key":"10114_CR135","doi-asserted-by":"publisher","first-page":"712","DOI":"10.4103\/1673-5374.266916","volume":"15","author":"YC Lv","year":"2020","unstructured":"Lv YC, Gao AB, Yang J, Zhong LY, Jia B, Ouyang SH, Gui L, Peng TH, Sun S, Cayabyab F (2020) Long-term adenosine A1 receptor activation-induced sortilin expression promotes \u03b1-synuclein upregulation in dopaminergic neurons. Neural Regen Res 15:712\u2013723. https:\/\/doi.org\/10.4103\/1673-5374.266916","journal-title":"Neural Regen Res"},{"key":"10114_CR136","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00043","volume":"12","author":"DO Borroto-Escuela","year":"2018","unstructured":"Borroto-Escuela DO, Hinz S, Navarro G, Franco R, M\u00fcller CE, Fuxe K (2018) Understanding the role of adenosine A2AR heteroreceptor complexes in neurodegeneration and neuroinflammation. Front Neurosci 12:43. https:\/\/doi.org\/10.3389\/fnins.2018.00043","journal-title":"Front Neurosci"},{"key":"10114_CR137","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/jnc.14018","volume":"141","author":"EK Jackson","year":"2017","unstructured":"Jackson EK, Kotermanski SE, Menshikova EV, Dubey RK, Jackson TC, Kochanek PM (2017) Adenosine production by brain cells. J Neurochem 141:676\u2013693. https:\/\/doi.org\/10.1111\/jnc.14018","journal-title":"J Neurochem"},{"key":"10114_CR138","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.neuroscience.2013.04.057","volume":"246","author":"AA Pavlovsky","year":"2013","unstructured":"Pavlovsky AA, Boehning D, Li D, Zhang Y, Fan X, Green TA (2013) Psychological stress, cocaine and natural reward each induce endoplasmic reticulum stress genes in rat brain. Neuroscience 246:160\u2013169. https:\/\/doi.org\/10.1016\/j.neuroscience.2013.04.057","journal-title":"Neuroscience"},{"key":"10114_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00560","volume":"13","author":"E Colla","year":"2019","unstructured":"Colla E (2019) Linking the endoplasmic reticulum to Parkinson\u2019s disease and alpha-synucleinopathy. Front Neurosci 13:560. https:\/\/doi.org\/10.3389\/fnins.2019.00560","journal-title":"Front Neurosci"},{"key":"10114_CR140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10787-022-01087-8","volume":"31","author":"GES Batiha","year":"2023","unstructured":"Batiha GES, Al-kuraishy HM, Al-Gareeb AI, Alruwaili M, AlRuwaili R, Albogami SM, Alorabi M, Saad HM, Simal-Gandara J (2023) Targeting of neuroinflammation by glibenclamide in COVID-19: old weapon from arsenal. Inflammopharmacology 31:1\u20137. https:\/\/doi.org\/10.1007\/s10787-022-01087-8","journal-title":"Inflammopharmacology"},{"key":"10114_CR141","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/805198","author":"F Pedata","year":"2014","unstructured":"Pedata F, Pugliese AM, Coppi E, Dettori I, Maraula G, Cellai L, Melani A (2014) Adenosine A 2A receptors modulate acute injury and neuroinflammation in brain ischemia. Mediators Inflamm. https:\/\/doi.org\/10.1155\/2014\/805198","journal-title":"Mediators Inflamm"},{"key":"10114_CR142","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071739","author":"A Mart\u00ed Navia","year":"2020","unstructured":"Mart\u00ed Navia A, Dal Ben D, Lambertucci C, Spinaci A, Volpini R, Marques-Morgado I, Coelho JE, Lopes LV, Marucci G, Buccioni M (2020) Adenosine receptors as neuroinflammation modulators: role of A1 agonists and A2A antagonists. Cells. https:\/\/doi.org\/10.3390\/cells9071739","journal-title":"Cells"},{"key":"10114_CR143","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0365","author":"M Synowitz","year":"2006","unstructured":"Synowitz M, Glass R, F\u00e4rber K, Markovic D, Kronenberg G, Herrmann K, Schnermann J, Nolte C, Van Rooijen N, Kiwit J, Kettenmann H (2006) A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0365","journal-title":"Cancer Res"},{"key":"10114_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53627-y","author":"ID Aires","year":"2019","unstructured":"Aires ID, Madeira MH, Boia R, Rodrigues-Neves AC, Martins JM, Ambr\u00f3sio AF, Santiago AR (2019) Intravitreal injection of adenosine A2A receptor antagonist reduces neuroinflammation, vascular leakage and cell death in the retina of diabetic mice. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-019-53627-y","journal-title":"Sci Rep"},{"key":"10114_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-023-00742-2","volume":"29","author":"NH Ali","year":"2023","unstructured":"Ali NH, Al-kuraishy HM, Al-Gareeb AI, Alnaaim SA, Alexiou A, Papadakis M, Saad HM, Batiha GES (2023) Autophagy and autophagy signaling in epilepsy: possible role of autophagy activator. Mol Med 29:142. https:\/\/doi.org\/10.1186\/s10020-023-00742-2","journal-title":"Mol Med"},{"key":"10114_CR146","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","volume":"432","author":"X Hou","year":"2020","unstructured":"Hou X, Watzlawik JO, Fiesel FC, Springer W (2020) Autophagy in Parkinson\u2019s disease. J Mol Biol 432:2651\u20132672. https:\/\/doi.org\/10.1016\/j.jmb.2020.01.037","journal-title":"J Mol Biol"},{"key":"10114_CR147","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00395-009-0006-6","volume":"104","author":"S Yitzhaki","year":"2009","unstructured":"Yitzhaki S, Huang C, Liu W, Lee Y, Gustafsson \u00c5B, Mentzer RM, Gottlieb RA (2009) Autophagy is required for preconditioning by the adenosine A1 receptor-selective agonist CCPA. Basic Res Cardiol 104:157\u2013167. https:\/\/doi.org\/10.1007\/s00395-009-0006-6","journal-title":"Basic Res Cardiol"},{"key":"10114_CR148","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41419-018-0316-4","volume":"9","author":"XJ Zeng","year":"2018","unstructured":"Zeng XJ, Li P, Ning YL, Zhao Y, Peng Y, Yang N, Zhao ZA, Chen JF, Zhou YG (2018) Impaired autophagic flux is associated with the severity of trauma and the role of A2AR in brain cells after traumatic brain injury article. Cell Death Dis 9:252. https:\/\/doi.org\/10.1038\/s41419-018-0316-4","journal-title":"Cell Death Dis"},{"key":"10114_CR149","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1080\/15548627.2020.1741202","volume":"17","author":"S Pi","year":"2021","unstructured":"Pi S, Mao L, Chen J, Shi H, Liu Y, Guo X, Li Y, Zhou L, He H, Yu C, Liu J, Dang Y, Xia Y, He Q, Jin H, Li Y, Hu Y, Miao Y, Yue Z, Hu B (2021) The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis. Autophagy 17:980\u20131000. https:\/\/doi.org\/10.1080\/15548627.2020.1741202","journal-title":"Autophagy"},{"key":"10114_CR150","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antiox9090902","volume":"9","author":"M Ikram","year":"2020","unstructured":"Ikram M, Park TJ, Ali T, Kim MO (2020) Antioxidant and neuroprotective effects of caffeine against Alzheimer\u2019s and parkinson\u2019s disease: insight into the role of Nrf-2 and A2AR signaling. Antioxidants 9:1\u201321. https:\/\/doi.org\/10.3390\/antiox9090902","journal-title":"Antioxidants"},{"key":"10114_CR151","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jsps.2020.02.005","volume":"28","author":"F Alasmari","year":"2020","unstructured":"Alasmari F (2020) Caffeine induces neurobehavioral effects through modulating neurotransmitters. Saudi Pharm J 28:445\u2013451. https:\/\/doi.org\/10.1016\/j.jsps.2020.02.005","journal-title":"Saudi Pharm J"},{"key":"10114_CR152","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1023\/A:1023688604792","volume":"23","author":"D Shi","year":"2003","unstructured":"Shi D, Padgett WL, Daly JW (2003) Caffeine analogs: effects on ryanodine-sensitive calcium-release channels and GABAA receptors. Cell Mol Neurobiol 23:331\u2013347. https:\/\/doi.org\/10.1023\/A:1023688604792","journal-title":"Cell Mol Neurobiol"},{"key":"10114_CR153","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s11302-020-09724-z","volume":"16","author":"RS Martins","year":"2020","unstructured":"Martins RS, Rombo DM, Gon\u00e7alves-Ribeiro J, Meneses C, Borges-Martins VPP, Ribeiro JA, Vaz SH, Kubrusly RCC, Sebasti\u00e3o AM (2020) Caffeine has a dual influence on NMDA receptor\u2013mediated glutamatergic transmission at the hippocampus. Purinergic Signal 16:503\u2013518. https:\/\/doi.org\/10.1007\/s11302-020-09724-z","journal-title":"Purinergic Signal"},{"key":"10114_CR154","doi-asserted-by":"publisher","unstructured":"Zhou ZD, Xie SP, Saw WT, Ho PGH, Wang H, Lei Z, Yi Z, Tan EK (2019) The therapeutic implications of tea polyphenols against dopamine (DA) neuron degeneration in parkinson\u2019s disease (PD). Cells\u00a08:911. https:\/\/doi.org\/10.3390\/cells8080911","DOI":"10.3390\/cells8080911"},{"key":"10114_CR155","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bbr.2014.01.051","volume":"264","author":"JA Machado-Filho","year":"2014","unstructured":"Machado-Filho JA, Correia AO, Montenegro ABA, Nobre MEP, Cerqueira GS, Neves KRT, da G. Naffah-Mazzacoratti M, Cavalheiro EA, de Castro Brito GA, De Barros Viana GS (2014) Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions. Behav Brain Res 264:116\u2013125. https:\/\/doi.org\/10.1016\/j.bbr.2014.01.051","journal-title":"Behav Brain Res"},{"key":"10114_CR156","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.neuint.2015.11.006","volume":"92","author":"P Bagga","year":"2016","unstructured":"Bagga P, Chugani AN, Patel AB (2016) Neuroprotective effects of caffeine in MPTP model of Parkinson\u2019s disease: a 13C NMR study. Neurochem Int 92:25\u201334. https:\/\/doi.org\/10.1016\/j.neuint.2015.11.006","journal-title":"Neurochem Int"},{"key":"10114_CR157","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2018.00301","volume":"12","author":"Y Luan","year":"2018","unstructured":"Luan Y, Ren X, Zheng W, Zeng Z, Guo Y, Hou Z, Guo W, Chen X, Li F, Chen JF (2018) Chronic caffeine treatment protects against \u03b1-synucleinopathy by reestablishing autophagy activity in the mouse striatum. Front Neurosci 12:12. https:\/\/doi.org\/10.3389\/fnins.2018.00301","journal-title":"Front Neurosci"},{"key":"10114_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2016.02.035","author":"K Xu","year":"2016","unstructured":"Xu K, Di Luca DG, Orr\u00fa M, Xu Y, Chen JF, Schwarzschild MA (2016) Neuroprotection by caffeine in the MPTP model of parkinson\u2019s disease and its dependence on adenosine A2A receptors. Neuroscience. https:\/\/doi.org\/10.1016\/j.neuroscience.2016.02.035","journal-title":"Neuroscience"},{"key":"10114_CR159","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.pbb.2006.05.027","volume":"84","author":"LMV Aguiar","year":"2006","unstructured":"Aguiar LMV, Nobre HV, Mac\u00eado DS, Oliveira AA, Freitas RM, Vasconcelos SM, Cunha GMA, Sousa FCF, Viana GSB (2006) Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol Biochem Behav 84:415\u2013419. https:\/\/doi.org\/10.1016\/j.pbb.2006.05.027","journal-title":"Pharmacol Biochem Behav"},{"key":"10114_CR160","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/B978-0-12-801022-8.00012-X","volume":"119","author":"JF Chen","year":"2014","unstructured":"Chen JF (2014) Adenosine receptor control of cognition in normal and disease. Int Rev Neurobiol 119:257\u2013307. https:\/\/doi.org\/10.1016\/B978-0-12-801022-8.00012-X","journal-title":"Int Rev Neurobiol"},{"key":"10114_CR161","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neuropharm.2016.07.012","volume":"110","author":"WKD Ko","year":"2016","unstructured":"Ko WKD, Camus SM, Li Q, Yang J, McGuire S, Pioli EY, Bezard E (2016) An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models. Neuropharmacology 110:48\u201358. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.07.012","journal-title":"Neuropharmacology"},{"key":"10114_CR162","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.neuropharm.2013.01.002","volume":"70","author":"MM Acu\u00f1a-Lizama","year":"2013","unstructured":"Acu\u00f1a-Lizama MM, Bata-Garc\u00eda JL, Alvarez-Cervera FJ, G\u00f3ngora-Alfaro JL (2013) Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats. Neuropharmacology 70:51\u201362. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.01.002","journal-title":"Neuropharmacology"},{"key":"10114_CR163","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.bbr.2014.05.020","volume":"270","author":"L L\u00f3pez-Cruz","year":"2014","unstructured":"L\u00f3pez-Cruz L, Pardo M, Salamone JD, Correa M (2014) Differences between the nonselective adenosine receptor antagonists caffeine and theophylline in motor and mood effects: Studies using medium to high doses in animal models. Behav Brain Res 270:213\u2013222. https:\/\/doi.org\/10.1016\/j.bbr.2014.05.020","journal-title":"Behav Brain Res"},{"key":"10114_CR164","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2015.09.028","volume":"766","author":"SI Uchida","year":"2015","unstructured":"Uchida SI, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, Kanda T (2015) The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol 766:25\u201330. https:\/\/doi.org\/10.1016\/j.ejphar.2015.09.028","journal-title":"Eur J Pharmacol"},{"key":"10114_CR165","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166415","author":"J Lu","year":"2016","unstructured":"Lu J, Cui J, Li X, Wang X, Zhou Y, Yang W, Chen M, Zhao J, Pei G (2016) An anti-Parkinson\u2019s disease drug via targeting adenosine a2a receptor enhances amyloid-\u03b2 generation and \u03b3-secretase activity. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0166415","journal-title":"PLoS ONE"},{"key":"10114_CR166","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1474-4422(16)30329-5","volume":"16","author":"N Majbour","year":"2017","unstructured":"Majbour N, El-Agnaf O (2017) Cognitive impairment in Parkinson\u2019s disease. Lancet Neurol 16:23. https:\/\/doi.org\/10.1016\/S1474-4422(16)30329-5","journal-title":"Lancet Neurol"},{"key":"10114_CR167","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/sj.ejcn.1602788","volume":"62","author":"K S\u00e4\u00e4ksj\u00e4rvi","year":"2008","unstructured":"S\u00e4\u00e4ksj\u00e4rvi K, Knekt P, Rissanen H, Laaksonen MA, Reunanen A, M\u00e4nnist\u00f6 S (2008) Prospective study of coffee consumption and risk of Parkinson\u2019s disease. Eur J Clin Nutr 62:908\u2013915. https:\/\/doi.org\/10.1038\/sj.ejcn.1602788","journal-title":"Eur J Clin Nutr"},{"key":"10114_CR168","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/ggi.12123","volume":"14","author":"H Qi","year":"2014","unstructured":"Qi H, Li S (2014) Dose-response meta-analysis on coffee, tea and caffeine consumption with risk of Parkinson\u2019s disease. Geriatr Gerontol Int 14:430\u2013439. https:\/\/doi.org\/10.1111\/ggi.12123","journal-title":"Geriatr Gerontol Int"},{"key":"10114_CR169","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1212\/WNL.0b013e318263570d","volume":"79","author":"RB Postuma","year":"2012","unstructured":"Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Romenets SR, Altman R, Chuang R, Shah B (2012) Caffeine for treatment of Parkinson disease: A randomized controlled trial. Neurology 79:651\u2013658. https:\/\/doi.org\/10.1212\/WNL.0b013e318263570d","journal-title":"Neurology"},{"key":"10114_CR170","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3233\/JPD-191882","volume":"10","author":"R Bakshi","year":"2020","unstructured":"Bakshi R, MacKlin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA (2020) Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson\u2019s Disease in the Harvard Biomarkers Study. J Parkinsons Dis 10:505\u2013510. https:\/\/doi.org\/10.3233\/JPD-191882","journal-title":"J Parkinsons Dis"},{"key":"10114_CR171","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev-nutr-071816-064941","volume":"37","author":"G Grosso","year":"2017","unstructured":"Grosso G, Godos J, Galvano F, Giovannucci EL (2017) Coffee, caffeine, and health outcomes: an umbrella review. Annu Rev Nutr 37:131\u2013156. https:\/\/doi.org\/10.1146\/annurev-nutr-071816-064941","journal-title":"Annu Rev Nutr"},{"key":"10114_CR172","doi-asserted-by":"publisher","unstructured":"Hong CT, Chan L, Bai CH (2023) Correction: the effect of caffeine on the risk and progression of Parkinson\u2019s disease: a meta-analysis (Nutrients, (2020), 12, (1860), 10.3390\/nu12061860). Nutrients 15:1860. https:\/\/doi.org\/10.3390\/nu15030699","DOI":"10.3390\/nu15030699"},{"key":"10114_CR173","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201260","author":"T Ohmichi","year":"2018","unstructured":"Ohmichi T, Kasai T, Kosaka T, Shikata K, Tatebe H, Ishii R, Shinomoto M, Mizuno T, Tokuda T (2018) Biomarker repurposing: therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson\u2019s disease. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0201260","journal-title":"PLoS ONE"},{"key":"10114_CR174","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/mds.25319","volume":"28","author":"AMA Wills","year":"2013","unstructured":"Wills AMA, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA (2013) Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord 28:380\u2013383. https:\/\/doi.org\/10.1002\/mds.25319","journal-title":"Mov Disord"},{"key":"10114_CR175","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1212\/WNL.0000000000004568","volume":"89","author":"RB Postuma","year":"2017","unstructured":"Postuma RB, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D, Furtado S, Munhoz RP, Appel-Cresswell S, Moro A, Borys A, Hobson D, Lang AE (2017) Caffeine as symptomatic treatment for Parkinson disease (Caf\u00e9-PD). Neurology 89:1795\u20131803. https:\/\/doi.org\/10.1212\/WNL.0000000000004568","journal-title":"Neurology"},{"key":"10114_CR176","doi-asserted-by":"publisher","unstructured":"Kostic VS, Suetel M, Sternic N, Dragaseuic N, Przedborski S (1999) Theophylline increases\u00a0\u201con\u201d\u00a0time in advanced parkinsonian patients.\u00a0Neurology\u00a052:1916. https:\/\/doi.org\/10.1212\/WNL.52.9.1916","DOI":"10.1212\/WNL.52.9.1916"},{"key":"10114_CR177","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200201000-00005","author":"J Kulisevsky","year":"2002","unstructured":"Kulisevsky J, Barbanoj M, Gironell A, Antonijoan R, Casas M, Pascual-Sedano B (2002) A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson\u2019s disease. Clin Neuropharmacol. https:\/\/doi.org\/10.1097\/00002826-200201000-00005","journal-title":"Clin Neuropharmacol"},{"key":"10114_CR178","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.8.1154","author":"MA Schwarzschild","year":"2002","unstructured":"Schwarzschild MA, Chen JF, Ascherio A (2002) Caffeinated clues and the promise of adenosine A2a antagonists in PD. Neurology. https:\/\/doi.org\/10.1212\/WNL.58.8.1154","journal-title":"Neurology"},{"key":"10114_CR179","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.euroneuro.2023.03.006","volume":"71","author":"RW Hook","year":"2023","unstructured":"Hook RW, Isobe M, Savulich G, Grant JE, Ioannidis K, Christmas D, Sahakian BJ, Robbins TW, Chamberlain SR (2023) Role of adenosine A2A receptors in hot and cold cognition: effects of single-dose istradefylline in healthy volunteers. Eur Neuropsychopharmacol 71:55\u201364. https:\/\/doi.org\/10.1016\/j.euroneuro.2023.03.006","journal-title":"Eur Neuropsychopharmacol"},{"key":"10114_CR180","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25418","author":"Y Mizuno","year":"2013","unstructured":"Mizuno Y, Kondo T (2013) Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson\u2019s disease. Mov Disord. https:\/\/doi.org\/10.1002\/mds.25418","journal-title":"Mov Disord"},{"key":"10114_CR181","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18339-1","volume":"7","author":"W Sako","year":"2017","unstructured":"Sako W, Murakami N, Motohama K, Izumi Y, Kaji R (2017) The effect of istradefylline for Parkinson\u2019s disease: a meta-analysis. Sci Rep 7:18018. https:\/\/doi.org\/10.1038\/s41598-017-18339-1","journal-title":"Sci Rep"},{"key":"10114_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2022.136515","volume":"774","author":"XL Wang","year":"2022","unstructured":"Wang XL, Feng ST, Chen B, Hu D, Wang ZZ, Zhang Y (2022) Efficacy and safety of istradefylline for Parkinson\u2019s disease: a systematic review and meta-analysis. Neurosci Lett 774:136515. https:\/\/doi.org\/10.1016\/j.neulet.2022.136515","journal-title":"Neurosci Lett"},{"key":"10114_CR183","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jns.2018.11.005","volume":"396","author":"H Nagayama","year":"2019","unstructured":"Nagayama H, Kano O, Murakami H, Ono K, Hamada M, Toda T, Sengoku R, Shimo Y, Hattori N (2019) Effect of istradefylline on mood disorders in Parkinson\u2019s disease. J Neurol Sci 396:78\u201383. https:\/\/doi.org\/10.1016\/j.jns.2018.11.005","journal-title":"J Neurol Sci"},{"key":"10114_CR184","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jns.2017.07.045","volume":"380","author":"K Suzuki","year":"2017","unstructured":"Suzuki K, Miyamoto M, Miyamoto T, Uchiyama T, Watanabe Y, Suzuki S, Kadowaki T, Fujita H, Matsubara T, Sakuramoto H, Hirata K (2017) Istradefylline improves daytime sleepiness in patients with Parkinson\u2019s disease: an open-label, 3-month study. J Neurol Sci 380:230\u2013233. https:\/\/doi.org\/10.1016\/j.jns.2017.07.045","journal-title":"J Neurol Sci"},{"key":"10114_CR185","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","volume":"16","author":"HH Fernandez","year":"2010","unstructured":"Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM (2010) Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 16:16\u201320. https:\/\/doi.org\/10.1016\/j.parkreldis.2009.06.008","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-025-10114-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-025-10114-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-025-10114-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:01:40Z","timestamp":1777611700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-025-10114-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":185,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10114"],"URL":"https:\/\/doi.org\/10.1007\/s11302-025-10114-6","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}